Overview

Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation

Status:
Completed

Trial end date:
2009-08-01

Target enrollment:

Participant gender:

Summary

The objective of this trial is to determine the efficacy and safety of linaclotide administered to patients with chronic constipation (CC). The primary efficacy parameter is the percentage of patients in each treatment group that meet the protocol definition for Complete Spontaneous Bowel Movement (CSBM) Overall Responder

Phase:

Phase 3

Details

Lead Sponsor:

Forest Laboratories

Collaborator:

Ironwood Pharmaceuticals, Inc.

Treatments:

Linaclotide